MD
Pharmala Biotech Holdings Inc.
MDMA.CN · CNQ
$0.25 +2.04% (+$0.01)
1M +32.43%
Market Cap $27.3M
P/E Ratio -
Div. Yield -
ROE 72.15%
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/B 14.15x
P/S 21.54x
EV/EBITDA N/A
Growth
94 /100
Growing Book val. growth 8.84%
Rev. growth 97.94%
FCF growth N/A
Profitability
0 /100
Weak Net margin 126.87%
Op. margin 120.21%
FCF margin 78.39%
Quality
5 /100
Poor ROE 72.15%
ROA 52.39%
Asset turnover 0.41x
Debt
83 /100
Low Current ratio 1.17x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
26 /100
Unstable Rev. volatility 327.52%
EPS volatility 84.68%
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o MDMA.CN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Nicholas Kadysh
Employees
5
Headquarters
Vancouver